Cogent Biosciences, Inc.
Clinical trials sponsored by Cogent Biosciences, Inc., explained in plain language.
-
New targeted drug shows promise for Hard-to-Treat cancers with FGFR mutations
Disease control OngoingThis study tests a new drug called CGT4859 in people with bile duct cancer (cholangiocarcinoma) or other advanced solid tumors that have specific genetic changes (FGFR2 or FGFR3). The goal is to find the best dose and see if the drug can shrink tumors or slow their growth. About …
Phase: PHASE1, PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for hard-to-treat GIST: combo therapy targets tumor growth
Disease control OngoingThis study tests whether adding a new drug (CGT9486) to standard sunitinib helps people with advanced gastrointestinal stromal tumors (GIST) that no longer respond to imatinib. About 442 adults with inoperable or spreading GIST will receive either the combo or sunitinib alone. Th…
Phase: PHASE3 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for mastocytosis patients: drug trial targets debilitating symptoms
Symptom relief OngoingThis study tests an experimental drug called bezuclastinib (CGT9486) in adults with nonadvanced systemic mastocytosis, a rare disease where too many mast cells cause symptoms like flushing, itching, and stomach issues. About 237 participants will receive either the drug or a plac…
Phase: PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Symptom relief
Last updated May 15, 2026 11:55 UTC